Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients – Dr Kaushik Biswas
Introduction India's T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1). The CMBCD framework highlights the interrelated…